

Reference List

Kostadin Kostadinov

References

- [1] Nicolas Garnier et al. “Genetic newborn screening and digital technologies: A project protocol based on a dual approach to shorten the rare diseases diagnostic path in Europe”. en. In: *PLOS ONE* 18.11 (Nov. 2023), e0293503. ISSN: 1932-6203. DOI: [10.1371/journal.pone.0293503](https://doi.org/10.1371/journal.pone.0293503). URL: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0293503>.
- [2] Kaloyan Guevara and Kostadin Kostadinov. “Neurological Soft Signs and Social Cognition in Patients with Schizophrenia: the Missing Link”. In: *Proceedings of the Bulgarian Academy of Sciences* 76.9 (Oct. 2023), pp. 1440–1448. DOI: [10.7546/CRABS.2023.09.15](https://doi.org/10.7546/CRABS.2023.09.15). URL: <https://www.proceedings.bas.bg/index.php/cr/article/view/391>.
- [3] M. Hubenova and K. Kostadinov. “Change in eating habits during the COVID-19 confinement”. In: *General Medicine* 24.1 (2022), pp. 23–29. URL: <https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131335656&partnerID=40&md5=960321f2fcf677479ecd9d43d8f6d6d0>.
- [4] Valentina Ignatova et al. “Socio-Economic Burden of Myasthenia Gravis: A Cost-of-Illness Study in Bulgaria”. In: *Front. Public Health* 10 (Mar. 2022). DOI: [10.3389/fpubh.2022.822909](https://doi.org/10.3389/fpubh.2022.822909). URL: <https://doi.org/10.3389/fpubh.2022.822909>.
- [5] Georgi Iskrov et al. “Are the European reference networks for rare diseases ready to embrace machine learning? A mixed-methods study”. In: *Orphanet Journal of Rare Diseases* 19.1 (Jan. 2024), p. 25. ISSN: 1750-1172. DOI: [10.1186/s13023-024-03047-7](https://doi.org/10.1186/s13023-024-03047-7). URL: <https://doi.org/10.1186/s13023-024-03047-7>.
- [6] Peter Kelly et al. “Trauma Informed Interventions to Reduce Seclusion, Restraint and Restrictive Practices Amongst Staff Caring for Children and Adolescents with Challenging Behaviours: A Systematic Review”. In: *Journal of Child and Adolescent Trauma* (Mar. 2023). ISSN: 1936-153X. DOI: [10.1007/s40653-023-00524-2](https://doi.org/10.1007/s40653-023-00524-2). URL: <http://dx.doi.org/10.1007/s40653-023-00524-2>.

- [7] Faik Kiani et al. “Dentophobia-latent Component Factor Analysis of Dental Concerns Assessment Scale”. In: *Open Access Maced J Med Sci* 11.E (Jan. 2023), pp. 53–58. DOI: [10.3889/oamjms.2023.9749](https://doi.org/10.3889/oamjms.2023.9749). URL: <https://doi.org/10.3889%2Foamjms.2023.9749>.
- [8] Kostadin Kostadinov and Nina Musurlieva. “Historical Overview of the Definition of Rare Tumors in the Context of Health Policies”. bg. In: *Rare Diseases and Orphan Drugs Journal* 14.2 (Nov. 2023), pp. 6–12. ISSN: 1314-3581. DOI: [10.36865/2023.v14i2.182](https://journal.raredis.org/index.php/RBLS/article/view/182). URL: <https://journal.raredis.org/index.php/RBLS/article/view/182>.
- [9] Kostadin Kostadinov et al. “Epidemiology of Acquired Thrombotic Thrombocytopenic Purpura”. In: *Rare Diseases and Orphan Drugs* 11.3 (Oct. 2020), pp. 36–44. ISSN: 1314-3581. DOI: [10.36865/2020.v11i3.122](https://journal.raredis.org/index.php/RBLS/article/view/122). URL: <https://journal.raredis.org/index.php/RBLS/article/view/122>.
- [10] Kostadin Kostadinov et al. “Navigating Gene Therapy Access: The Case of Bulgaria in the Context of the EU Regulatory Landscape”. en. In: *Healthcare* 12.4 (Jan. 2024), p. 458. ISSN: 2227-9032. DOI: [10.3390/healthcare12040458](https://www.mdpi.com/2227-9032/12/4/458). URL: <https://www.mdpi.com/2227-9032/12/4/458>.
- [11] R Raycheva and K Kostadinov. “HTA69 Delay of Innovative Oncology Treatments - Case From Bulgaria”. In: *Value in Health* 25.12 (Dec. 2022), S309–S310. ISSN: 1098-3015. DOI: [10.1016/j.jval.2022.09.1529](http://dx.doi.org/10.1016/j.jval.2022.09.1529). URL: <http://dx.doi.org/10.1016/j.jval.2022.09.1529>.
- [12] R. Raycheva and K. Kostadinov. “HTA7 The Price of Innovation – Oncology Treatments Expenditures: Case from Bulgaria”. en. In: *Value in Health* 26.6 (June 2023), S260. ISSN: 10983015. DOI: [10.1016/j.jval.2023.03.1436](https://linkinghub.elsevier.com/retrieve/pii/S109830152301536X). URL: <https://linkinghub.elsevier.com/retrieve/pii/S109830152301536X>.
- [13] Ralitsa Raycheva et al. “Challenges in mapping European rare disease databases, relevant for ML-based screening technologies in terms of organizational, FAIR and legal principles: scoping review”. In: *Frontiers in Public Health* 11 (2023). ISSN: 2296-2565. DOI: [10.3389/fpubh.2023.1214766](https://www.frontiersin.org/articles/10.3389/fpubh.2023.1214766). URL: <https://www.frontiersin.org/articles/10.3389/fpubh.2023.1214766>.
- [14] Editor RBLS. “6th National Conference on Rare Diseases and Orphan Drugs - Abstract Collection”. In: *Rare Diseases and Orphan Drugs Journal* 6.1 (Nov. 2019). ISSN: 1314-3581. DOI: [10.36865/2015.v6i1.92](http://journal.raredis.org/index.php/RBLS/article/view/92). URL: <http://journal.raredis.org/index.php/RBLS/article/view/92>.